Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.

  title={Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.},
  author={Werner Aberer and Marcus Maurer and Avner Reshef and H Longhurst and Shmuel Kivity and Anette Bygum and T Caballero and Benjamin Bloom and Nitya Nair and Alejandro Malbr{\'a}n},
  volume={69 3},
BACKGROUND Historically, treatment for hereditary angioedema (HAE) attacks has been administered by healthcare professionals (HCPs). Patient self-administration could reduce delays between symptom onset and treatment, and attack burden. The primary objective was to assess the safety of self-administered icatibant in patients with HAE type I or II. Secondary objectives included patient convenience and clinical efficacy of self-administration. METHODS In this phase IIIb, open-label, multicenter… CONTINUE READING
Highly Cited
This paper has 30 citations. REVIEW CITATIONS
Related Discussions
This paper has been referenced on Twitter 7 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 16 extracted citations

Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology • 2018
View 1 Excerpt

The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries

Journal of the European Academy of Dermatology and Venereology : JEADV • 2017